Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
Unifinz Capital India reported Q1FY27 net profit of ₹1.735 crore, raised its NCD umbrella limit to ₹1,000 crore, and scheduled an August 12 committee meeting for a private placement plan.
Axis Solutions secured a ₹400 crore domestic rural water supply order from NKG Primus JV, with execution running to March 2028 and a 3% performance guarantee.
Oxford Industries has proposed a 99% paid-up capital reduction to set off accumulated losses, alongside board-level changes, auditor replacement, and a strategic shift beyond textiles.
Mishtann Foods’ Q1FY26 net profit fell to ₹0.50 crore and revenue to ₹18.29 crore, while auditors issued a qualified opinion citing going-concern uncertainty and compliance gaps.
Jain Resource Recycling reported 76% YoY revenue growth in Q1 FY27 with lower EBITDA margin, and published its Aug 4 earnings call recording alongside IPO fund-use updates.
Park Medi World reported Q1FY27 revenue growth of 19% and net profit growth of 35%, and published its earnings call audio recording for investor access.
Prajay Engineers Syndicate reported a narrower FY26 consolidated loss and mixed quarterly trends, while the stock traded around ₹21 amid steady promoter holding and recent board approvals.
Affle 3i reported Q1 FY27 revenue of ₹747.16 crore and PAT of ₹128.44 crore, alongside acquisition and fundraising moves, while a Bobble AI dispute remains in focus.
Mangalam Cement posted a 44% YoY drop in Q1FY27 profit despite a 1% revenue rise, as finance costs and depreciation weighed on profitability.
Orbit Exports posted higher Q1FY27 earnings on a 15% revenue rise, while its board approved results, declared a 5% interim dividend, and completed a buyback.
Lumax Industries reported Q1FY27 earnings with consolidated profit up 41% and revenue up 33%, alongside a ₹55 final dividend recommendation and an August 11 earnings call.
Rapicut Carbides swung to Q1 FY26 profit as revenue jumped eight-fold year-on-year, while the board approved results, appointed a new CFO, and set the AGM date.
Akums Drugs & Pharmaceuticals will consider audited results and a FY2026 dividend on August 08, 2026, as investors track margins, segment performance, and recent price moves.
Affle 3i reported Q1 FY27 revenue of ₹747.16 crore and PAT of ₹128.44 crore, while standalone profit rose 37.5% after board approval and auditor review.
Affle 3i reported Q1 FY27 growth with consolidated revenue rising 20.4% to ₹747.16 crore and PAT up 21.7% to ₹128.44 crore, alongside an Aug 10 earnings call.
Affle 3i posted Q1 FY27 consolidated revenue of ₹747.16 crore (+20.4% YoY) and PAT of ₹128.44 crore (+21.7%), with an investor call scheduled for August 10, 2026.